News & Updates

The fully human-derived B-cell maturation antigen-targeting chimeric antigen receptor (CAR) T-cell therapy equecabtagene autoleucel (eque-cel) appears to induce early, deep, and lasting responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM), according to the results of the phase Ib/II FUMANBA-1 trial.

Using atezolizumab in addition to pertuzumab plus high-dose trastuzumab does not appear to improve central nervous system (CNS) responses in HER2-positive breast cancer patients with brain metastases, according to the results of a single-arm phase II study.

Quitting smoking within 6 months after receiving a cancer diagnosis appears to confer survival benefits, according to a study.

Including adjuvant nivolumab as part of a perioperative regimen for resectable NSCLC further improves the EFS benefit vs including nivolumab in a neoadjuvant-only setting, as suggested by a patient-level data analysis of CheckMate 77T and CheckMate 816 investigating each modality separately

Treatment with aumolertinib significantly prolonged progression-free survival (PFS) compared with placebo in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) who did not experience disease progression following chemoradiotherapy (CRT), according to a preplanned interim analysis of the phase III POLESTAR trial presented at WCLC 2024. 

New drug applications approved by US FDA as of 16-31 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Rapid infusion of oxaliplatin appears to have minimal treatment modifications relative to standard administration but may lead to a higher incidence of peripheral neuropathy (PN), according to a study.